HI
LAB icon

HBK Investments’s Standard BioTools LAB Stock Holding History

HBK Investments’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-150,781
Closed -$333K – 199
2023
Q4 		$333K Buy
+150,781
New +$322K ﹤0.01% 202
2014
Q2 		– Sell
-15,350
Closed -$676K – 980
2014
Q1 		$676K Buy
+15,350
New +$675K 0.01% 583

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

HBK Investments's LAB Position: Q1 2024 in Review

HBK Investments sold out of Standard BioTools (LAB) in Q1 2024, closing a stake of 150,781 shares — an estimated $333K sold.

HBK Investments first reported a position in LAB in Q1 2014 and held it in 2 quarters. The position peaked at $676K in Q1 2014. 145 funds tracked by Wall St. Rank hold LAB as of Q1 2024.

  • HBK Investments reported no remaining Standard BioTools position as of Q1 2024 after selling out during the quarter.
  • HBK Investments sold 150,781 Standard BioTools shares in Q1 2024, an estimated $333K.
  • HBK Investments first reported a position in Standard BioTools in Q1 2014 and held it in 2 quarters.
  • HBK Investments's Standard BioTools position peaked at $676K in Q1 2014.
  • 145 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2024.

Based on HBK Investments's 13F filing for Q1 2024, filed 15 May 2024.